Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Combining IL-6 Measurement with a Standard Biomarker Panel Improves Diagnosis of Ovarian Cancer

By LabMedica International staff writers
Posted on 26 Feb 2020
Addition of the inflammatory biomarker IL-6 (interleukin-6) to a standard panel of tumor markers was found to enchance immunodiagnosis of ovarian cancer.

Ovarian cancer is one of the most common gynaecologic cancers and has the highest mortality rate. More...
About 300,000 new cases are diagnosed each year world wide, with an estimated 60% of patients dying within five years after diagnosis.

Since HGSOC (high-grade serous ovarian cancer) progression is correlated with local and systemic inflammation, investigators at RMIT University (Melbourne, Australia) hypothesised that inclusion of inflammatory biomarkers in sera may improve diagnostic tests.

To test this hypothesis, the investigators used four existing clinical tests (RMI score and ROMA, CA125, and HE4) and a panel of 28 immune soluble biomarkers in sera from 66 patients undergoing surgery for suspected ovarian cancer. For this study, multiplex magnetic bead immunoassay kits were used to simultaneously measure 28 analytes in a single sample. This allowed quantitative measurement of cytokines (GM-CSF, IFN-alpha, IFN-gamma, IL-1beta, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17 and TNF-alpha) and chemokines (RANTES, Eotaxin, CCL2/MCP-1, CCL3/MIP-1alpha, CCL4/ MIP-1beta, CXCL9/MIG, CXCL10/IP-10) in patient’s serum.

Six promising immune biomarkers alone, or in combination with conventional tests, were subsequently analyzed in an independent validation cohort of 69 patients. The cytokine IL-6 was identified as the main driver of variability followed closely by conventional diagnostic tests. Median sera IL-6 was higher in HGSOC patients compared to those with a benign mass or controls with normal ovaries. The combination of IL-6 further improved the overall predictive probability of the conventional tests.

"Our new test is as accurate as the combined results of a standard blood test and ultrasound," said senior author Dr. Magdalena Plebanski, professor of immunology at RMIT University. "This is especially important for women in remote or disadvantaged communities, where under-resourced hospitals may not have access to complex and expensive equipment like ultrasound machines or MRI scanners. It also means patients with benign cysts identified through imaging could potentially be spared unnecessary surgeries. This study looked at women with advanced ovarian cancer, but we hope further research could explore the potential for adding this biomarker to routine diagnostic tests at earlier stages of the disease."

Results of the study were published in the February 10, 20120, online edition of the journal Scientific Reports.

Related Links:
RMIT University


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.